T-DXd monotherapy or T-DXd sequential THP compared with ddAC-THP is being actively studied in the clinical trial DESTINY-Breast11 (DB11) for high-risk HER2-positive early breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.